283 related articles for article (PubMed ID: 1328412)
1. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
Preiksaitis JK; Diaz-Mitoma F; Mirzayans F; Roberts S; Tyrrell DL
J Infect Dis; 1992 Nov; 166(5):986-94. PubMed ID: 1328412
[TBL] [Abstract][Full Text] [Related]
2. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
3. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
4. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
5. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
6. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
8. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
Sprangers B; Riella LV; Dierickx D
Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
[TBL] [Abstract][Full Text] [Related]
10. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
11. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.
Limaye AP; Huang ML; Atienza EE; Ferrenberg JM; Corey L
J Clin Microbiol; 1999 Apr; 37(4):1113-6. PubMed ID: 10074534
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections].
Karadağ Geçgel S; Ersoy A; Sevinir BB; Sınırtaş M; Göral G
Mikrobiyol Bul; 2012 Oct; 46(4):594-606. PubMed ID: 23188573
[TBL] [Abstract][Full Text] [Related]
13. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
14. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
Birkeland SA; Andersen HK; Hamilton-Dutoit SJ
Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
[TBL] [Abstract][Full Text] [Related]
16. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
18. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
[TBL] [Abstract][Full Text] [Related]
19. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft.
Yousem SA; Randhawa P; Locker J; Paradis IL; Dauber JA; Griffith BP; Nalesnik MA
Hum Pathol; 1989 Apr; 20(4):361-9. PubMed ID: 2539321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
